ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients Data from preclinical studies of ORJ-001 ...
(RTTNews) - MiNK Therapeutics (INKT), a clinical-stage company, said new translational data supporting the role of invariant natural killer T or iNKT cells in idiopathic pulmonary fibrosis or IPF were ...
Rentosertib, an AI-discovered TNIK inhibitor, showed safety and tolerability in a phase 2a trial for idiopathic pulmonary fibrosis. The trial involved 71 patients, with similar adverse event rates ...
Idiopathic pulmonary fibrosis (IPF) is a life-threatening disease in which lung tissue becomes scarred, making it hard to ...
“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to ...
AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics (RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs ...
GRI Bio on track to launch Phase 2a biomarker study for lead program, GRI-0621 a type 1 invariant NKT (iNKT) antagonist for the treatment of IPF before year end LA JOLLA, CA, Oct. 19, 2023 (GLOBE ...
Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained intervention 1,2 CHMP’s positive opinion ...
Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening disease. It causes scarring of the connective tissue between the functional ...
If you have idiopathic pulmonary fibrosis (IPF), a chronic lung condition that can cause shortness of breath, low oxygen levels in the blood, and scarring on the lungs (fibrosis), it’s important to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results